Earnings release
Page 1
Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement , make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement . ATO ANTENGENE Antengene Corporation Limited 德琪 醫藥 有限公司 ( Incorporated in the Cayman Islands with limited liability ) ( Stock Code : 6996 ) ANNOUNCEMENT OF INTERIM RESULTS FOR THE SIX MONTHS ENDED JUNE 30 , 2021 The board of directors ( the “ Board ” ) of Antengene Corporation Limited ( the " Company " or “ Antengene ” ) is pleased to announce the unaudited condensed consolidated results of the Company and its subsidiaries ( together , the “ Group ” , “ we ” or “ us ” ) for the six months ended June 30 , 2021 ( the " Reporting Period ” ) , together with comparative figures for the six months ended June 30 , 2020. The consolidated financial statements of the Group for the Reporting Period have been reviewed by the Audit Committee of the Company . FINANCIAL HIGHLIGHTS For the six months ended June 30 , 2021 RMB ' 000 2020 RMB ' 000 ( Unaudited ) ( Audited ) Other income and gains 18,135 19,366 Research and development costs ( 135,333 ) ( 169,888 ) Administrative expenses ( 78,512 ) ( 68,681 ) Fair value loss on convertible redeemable preferred shares * ( 317,363 ) Loss for the period ( 232,995 ) ( 537,747 ) Total comprehensive loss for the period ( 227,685 ) ( 537,747 ) Adjusted loss for the period ** ( 209,860 ) ( 136,520 ) ** This represents the loss on the fair value changes of convertible redeemable preferred shares , a non - cash and one - time adjustment recognised upon listing as required under the International Financial Reporting Standards ( " IFRSS " ) . Adjusted loss for the period is not defined under the IFRS , it represents the loss for the period excluding the effect brought by equity - settled share option expense , share issue expenses and fair value loss on convertible redeemable preferred shares . 1